Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011074607 - TRITERPENE DERIVATIVE, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CHRONIC HEPATITIS C

Publication Number WO/2011/074607
Publication Date 23.06.2011
International Application No. PCT/JP2010/072564
International Filing Date 15.12.2010
IPC
C07J 63/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
JSTEROIDS
63Steroids in which the cyclopentahydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
08acyclic, e.g. paraformaldehyde
A61K 31/085 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
085having an ether linkage to aromatic ring nuclear carbon
A61K 31/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
A61K 31/135 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
A61K 31/136 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
136having the amino group directly attached to the aromatic ring, e.g. benzeneamine
CPC
A61K 31/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
08acyclic, e.g. paraformaldehyde
A61K 31/085
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
085having an ether linkage to aromatic ring nuclear carbon
A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
A61K 31/135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
A61K 31/136
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
136having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/185
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Applicants
  • Meiji Seikaファルマ株式会社 Meiji Seika Pharma Co., Ltd. [JP]/[JP] (AllExceptUS)
  • 石川 誠 ISHIKAWA Makoto [JP]/[JP] (UsOnly)
  • 鈴木 重輝 SUZUKI Shigeki [JP]/[JP] (UsOnly)
  • 青木 信 AOKI Makoto [JP]/[JP] (UsOnly)
  • 箕輪 宣人 MINOWA Nobuto [JP]/[JP] (UsOnly)
  • 鈴木 幸吉 SUZUKI Kokichi [JP]/[JP] (UsOnly)
Inventors
  • 石川 誠 ISHIKAWA Makoto
  • 鈴木 重輝 SUZUKI Shigeki
  • 青木 信 AOKI Makoto
  • 箕輪 宣人 MINOWA Nobuto
  • 鈴木 幸吉 SUZUKI Kokichi
Agents
  • 特許業務法人セントクレスト国際特許事務所 CENTCREST IP ATTORNEYS
Priority Data
2009-28413515.12.2009JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) TRITERPENE DERIVATIVE, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CHRONIC HEPATITIS C
(FR) DÉRIVÉ TRITERPÉNIQUE, ET AGENT PROPHYLACTIQUE OU THÉRAPEUTIQUE POUR L'HÉPATITE C CHRONIQUE
(JA) トリテルペン誘導体およびC型慢性肝炎の予防または治療のための薬剤
Abstract
(EN)
Disclosed is a triterpene derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed is a prophylactic or therapeutic agent for chronic hepatitis C, which contains the above-described triterpene derivative or a pharmaceutically acceptable salt thereof as an active ingredient. (In formula (I), R1 represents a carboxyl group, a hydroxymethyl group, -CH2OSO3H or a group represented by formula AA; R2 represents -OR3 or -O-(CH2)m-OR4; R3 represents a benzyl group which may be substituted by a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group or a hydroxy C1-6 alkyl group; R4 represents a phenyl group which may be substituted by a carboxyl group; and m represents an integer of 1-3. In this connection, the cases where R1 is -CH2OH and R3 is a C1-6 alkyl group, a C2-6 alkenyl group or a benzyl group are excluded.)
(FR)
L'invention concerne un dérivé triterpénique représenté par la formule générale (I) ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également un agent prophylactique ou thérapeutique pour l'hépatite C chronique, qui contient le dérivé triterpénique décrit ci-dessus ou un sel pharmaceutiquement acceptable de celui-ci comme ingrédient actif. [Dans la formule (I), R1 représente un groupe carboxyle, un groupe hydroxyméthyle, -CH2OSO3H ou un groupe représenté par la formule AA ; R2 représente -OR3 ou -O-(CH2)m-OR4 ; R3 représente un groupe benzyle qui peut être substitué par un groupe hydroxyméthyle, un groupe diméthylaminométhyle, un groupe phénylaminométhyle, un groupe morpholinométhyle, un groupe carboxyle ou un groupe formyle, un groupe alkyle en C1-6, un groupe alcényle en C2-6, un groupe alcynyle en C2-6 ou un groupe hydroxy (alkyle en C1-6) ; R4 représente un groupe phényle qui peut être substitué par un groupe carboxyle ; et m représente un nombre entier de 1 à 3. Dans le même sens, les cas dans lesquels R1 est -CH2OH et R3 est un groupe alkyle en C1-6, un groupe alcényle en C2-6 ou un groupe benzyle sont exclus.)
(JA)
 一般式(I)で示すトリテルペン誘導体または医薬的に許容されるその塩、およびそれを有効成分とするC型慢性肝炎の予防または治療のための薬剤を提供する。 [式(I)中、Rはカルボキシル基、ヒドロキシメチル基、-CHOSOH、または 式(Ⅱ)を表し、Rは-OR、または-O-(CH)m-ORを表す。ここで、Rはヒドロキシメチル基、ジメチルアミノメチル基、フェニルアミノメチル基、モルホリノメチル基、カルボキシル基もしくはホルミル基で置換されていてもよいベンジル基、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、またはヒドロキシC1-6アルキル基を表し、Rはカルボキシル基で置換されていてもよいフェニル基を表し、mは1~3の整数を表す。ただし、Rが-CHOHであり、かつ、RがC1-6アルキル基、C2-6アルケニル基またはベンジル基である場合は除く。]
Latest bibliographic data on file with the International Bureau